The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients  by Grossman, Eric B. et al.
Kidney International, Vol. 66 (2004), pp. 367–374
DIALYSIS – TRANSPLANTATION
The pharmacokinetics and hemodynamics of sildenafil citrate
in male hemodialysis patients
ERIC B. GROSSMAN, SUZANNE K. SWAN, GARY J. MUIRHEAD, MICHAEL GAFFNEY, MENGER CHUNG,
HERB DERIESTHAL, DIANE CHOW, and LEOPOLDO RAIJ
Pfizer, Inc., New York, New York; DaVita Clinical Research, Inc., Hennepin County Medical Center, Minneapolis, Minnesota; Pfizer,
Ltd., Sandwich, United Kingdom; and Veterans Affairs Medical Center, University of Miami School of Medicine, Miami, Florida
The pharmacokinetics and hemodynamics of sildenafil citrate
in male hemodialysis patients.
Background. Erectile dysfunction (ED) is highly prevalent
in men with renal disease. The clearance of sildenafil citrate,
a highly effective oral treatment for ED, is decreased in men
with severe renal insufficiency, but the pharmacokinetic and
hemodynamic profiles during maintenance hemodialysis in men
with end-stage renal disease have not been studied.
Methods. Fifteen men undergoing chronic outpatient main-
tenance hemodialysis received a single 50-mg oral dose of silde-
nafil on 2 occasions, once 2 hours before, and once 2 hours after
hemodialysis, with randomized assignment to sequence. Blood
and dialysate samples were collected, and hemodynamic mea-
surements were made.
Results. Hemodialysis did not significantly clear either silde-
nafil or its primary metabolite, UK-103,320. Administration af-
ter hemodialysis was associated with a 17% higher peak plasma
concentration and earlier time to peak, which were not clini-
cally meaningful, whereas the overall extent of absorption and
the elimination half-life were not affected. The average extent
of drug bound to plasma protein was approximately 96% in
hemodialysis patients. Intradialytic hypotension was not ob-
served more frequently when sildenafil was administered be-
fore hemodialysis. Systolic blood pressure tended to decrease
less during hemodialysis when subjects were treated with silde-
nafil before dialysis.
Conclusion. The present study demonstrates that sildenafil
is not cleared by hemodialysis, and the pharmacokinetic profile
resembles more closely that observed in normal volunteers than
that observed in patients with severe renal insufficiency. In ad-
dition, we found that sildenafil does not promote intradialytic
hypotension.
Erectile dysfunction (ED) is a condition that
is associated with cardiovascular diseases, including
atherosclerosis, hypertension, and diabetes mellitus, and
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increasingly is recognized as being a consequence of vas-
cular or endothelial dysfunction [1, 2]. The hemodialysis
patient population has a high incidence of cardiovascular
disease, and thus, it is not surprising that a majority of men
receiving maintenance hemodialysis experience ED [3–
6]. In a cross-sectional study of men from a community-
based hemodialysis population, the prevalence of any de-
gree of ED was 82%, and the prevalence of severe ED
was 45% [4]. Furthermore, ED in hemodialysis patients
has been shown to have a significant impact on quality
of life measures [7]. Sildenafil citrate, introduced in 1998,
is the first oral and most widely prescribed treatment for
ED. Several studies have indicated that sildenafil is a well-
tolerated and effective treatment for ED in men receiving
maintenance hemodialysis [8–10]; however, the pharma-
cokinetic and hemodynamic profiles of sildenafil in this
population, which are of interest from both clinical and
pathogenetic perspectives, have not been systematically
examined.
In healthy volunteers, sildenafil is extensively ab-
sorbed; however, rapid first-pass metabolism limits the
absolute bioavailability to approximately 40%, Cmax is
reached within 30 to 120 minutes of oral administration
in the fasted state, and the terminal half-life is about
4 hours [11]. Sildenafil is converted to a number of
metabolites by the hepatic P450 enzymes CYP3A4 and
CYP2C9. The primary N-demethylated product, UK-
103,320, has a slightly longer half-life, approximately
half the pharmacologic activity, and achieves approxi-
mately 40% of the plasma concentration of the parent
compound, resulting in approximately 14% of the total
pharmacologic effect of the drug [12, 13]. Both sildenafil
and UK-103,320 are more than 95% bound to plasma
proteins, independent of total drug concentrations [14].
Sildenafil is eliminated by hepatic metabolism and ex-
creted as metabolites predominantly in the feces (approx-
imately 80% of an oral dose), with only a small amount
excreted in the urine (approximately 13% of an oral dose)
[13]. In men with mild or moderate renal impairment,
the pharmacokinetics were not significantly different
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from those in normal men [12]. However, in patients
with severe renal insufficiency (creatinine clearance
<30 mL/min), the clearance of sildenafil is reduced by
half, resulting in an increased bioavailability [approxi-
mately doubled area under the curve (AUC) and max-
imum concentration of the drug (Cmax)] compared with
healthy normal volunteers [12].
Sildenafil acts through the nitric oxide-cGMP pathway
[15, 16], and enhanced nitric oxide (NO) biosynthesis has
been correlated with blood pressure decreases observed
during hemodialysis [17–21]. Previous studies did not
indicate adverse hemodynamic effects of sildenafil dur-
ing hemodialysis, but these studies did not systematically
evaluate blood pressure, nor did they control for the tim-
ing of sildenafil administration with respect to hemodial-
ysis therapy. Because sildenafil inhibits the breakdown of
NO-stimulated cyclic GMP [22], hemodialysis-associated
blood pressure changes observed in patients admin-
istered sildenafil should help test the hypothesis that
NO plays a role in the hemodynamic regulation during
hemodialysis.
Therefore, this study was designed to assess the phar-
macokinetics of a 50-mg dose of sildenafil in subjects with
end-stage renal disease (ESRD) (primary objective), and
to test the maximal hemodynamic effect by administering
sildenafil 2 hours before, and 2 hours after, hemodialysis.
METHODS
Subjects
Sixteen male subjects older than 18 years of age re-
ceiving routine outpatient hemodialysis therapy 3 times
weekly for at least 3 months, and having a hematocrit
greater than or equal to 32%, were recruited for partic-
ipation in this study. Subjects had to have a functioning
hemodialysis fistula, either native vein fistula or a gortex
graft, for use during the hemodialysis treatments. Men
who were taking nitrates or NO donors (e.g., nitroglyc-
erin or isosorbide dinitrate) in any form (oral, sublingual,
transdermal, inhalation, or aerosols) were specifically ex-
cluded from the study. Use of protease inhibitors or the
non-nucleoside reverse transcriptase inhibitor delavir-
dine were also prohibited because they inhibit the silde-
nafil metabolizing cytochrome P450 enzyme 3A4. Other
exclusion criteria were a resting systolic blood pressure
(SBP) of >180 or <90 mm Hg, or a resting sitting di-
astolic blood pressure (DBP) of >110 or <50 mm Hg,
>40% of their weight range for age, gender, height, and
frame, as established in the 1996 Metropolitan Life Insur-
ance Height and Weight Tables [23], report of hypoten-
sion during more than 3 hemodialysis treatments out of
the previous 36 treatments, a known history of retinitis
pigmentosa, a history of hypersensitivity reaction to the
dialysis membrane (polysulfone), and a known history
of hypersensitivity or previous intolerance to sildenafil
or any of the other tablet components. All subjects pro-
vided informed written consent before study entry. The
protocol was approval by the local Institutional Review
Board before study initiation.
Treatments
All subjects received treatment with a single 50-mg oral
dose of sildenafil citrate (Viagra; Pfizer, Inc., New York,
NY, USA) at each of 2 dosing phases, separated by an in-
terval of approximately 1 week. Hemodialysis treatments
were 3.5 hours in duration and used an F80A dialyzer
(Fresenius Medical Care, Lexington, MA, USA). Pro-
cedures were fixed for all patients through both phases.
Appropriate blood flow rate was determined by the in-
vestigator, and every effort was made to maintain the
flow at a constant flow rate above 300 mL/min through-
out the dialysis period. Needles used were 15-gauge, and
the dialysate flow rate was fixed at 500 mL/min. Dialysate
was bicarbonate-based and contained Na 140 mEq/L, and
K, HCO3, and Ca as appropriate. In phase A, hemodial-
ysis was started 2 hours after dosing with sildenafil, and
ended 5.5 hours after dosing. In phase B, hemodialysis
began 5.5 hours before dosing with sildenafil, and ended
2 hours before dosing (Fig. 1).
Study design
The study followed a randomized, 2-phase crossover,
open-label design, and was conducted at a single site (To-
tal Renal Research, Hennepin County Medical Center,
Minneapolis, MN, USA). There were a total of 3 study
visits. Subjects were screened no more than 2 weeks be-
fore the first dosing phase. At each of 2 dosing visits,
subjects were under observation through 48 and 42 hours
postdose for phases A and B, respectively. Subjects were
randomized to phase order (sequence). In phase A,
patients received sildenafil 2 hours before the start of
hemodialysis; in phase B, the same treatment was ad-
ministered 2 hours after the completion of hemodialysis
(Fig. 1). Blood and dialysate samples were collected for
analysis of sildenafil and UK-103,320 concentrations, and
hemodynamic measurements of blood pressure and heart
rate were performed at prespecified time points through
48 hours’ postdose in phase A, and 42 hours’ postdose in
phase B.
Pharmacokinetic sampling
Venous blood samples were collected for sildenafil and
UK-103,320 assays immediately before sildenafil dosing,
at 30-minute intervals through 6 hours’ postdosing (ex-
cept for 1.5 hours’ postdosing), and at 7, 8, 10, 12, 18, and
24 hours’ postdosing during both dosing phases. End-of-
phase venous blood samples were collected at 48 hours’
postdose in phase A and at 42 hours’ postdose in phase
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Fig. 1. Study design. In phase A, subjects re-
ceived a single oral dose of sildenafil (50 mg)
at time 0, 2 hours before the start of hemodial-
ysis (HD), which lasted 3.5 hours. In phase A,
inlet (arterial), outlet (venous), and dialysate
samples were collected for pharmacokinetic
(PK) determinations. In phase B, subjects re-
ceived a single oral dose of sildenafil (50 mg)
at time 0, 2 hours after the completion of HD.
In both phase A and phase B, venous blood
was drawn at regular intervals after sildenafil
administration for PK determinations. Blood
pressure (BP) and heart rate (HR) were mea-
sured at regular intervals for the duration of
both phases.
B. During dialysis in phase A, samples were collected ev-
ery 30 minutes simultaneously at the inlet (arterial) and
outlet (venous) sides of the dialyzer, as well as from the
dialysate.
Analytical methods
All plasma and dialysate samples were assayed for
sildenafil and UK-103,320 with a previously validated
method, which employed automatic sample prepara-
tion using an automated sequential trace enrichment
of dialysates (ASTED) method, and separation of the
analytes by reversed phase high-pressure liquid chro-
matography with subsequent ultraviolet detection [24].
The lower limit of quantification for all analyses was
1.00 ng/mL. The calibration curves for both analytes were
linear over the range of 1 to 250 ng/mL. The overall impre-
cision (coefficient of variation) was 5.1%, 3.2%, and 3.0%
for sildenafil and 3.4%, 3.1%, and 2.9% for UK-103,320
concentrations of 3.00, 125, and 200 ng/mL, respectively.
The inaccuracy (bias) of the assay at all concentrations
ranged from −2.3% to 3.5% for sildenafil and −7.0% to
4.8% for UK-103,320. Protein binding was determined
by equilibrium dialysis.
Hemodynamic measurements
Blood pressure and heart rate measurements were
performed immediately before sildenafil dosing, at 30-
minute intervals through 6 hours’ postdosing (except at
1.5 hours), and at 7, 8, 10, 12, 18, and 24 hours postdos-
ing throughout both dosing phases. In addition, in phase
B, blood pressure and heart rate were measured at 30-
minute intervals during hemodialysis, and 1 hour after
hemodialysis, before sildenafil dosing.
Data analysis
The following pharmacokinetic parameters were calcu-
lated: Cmax, Tmax (time from dosing to the first occurrence
of Cmax), kD (terminal elimination phase rate constant),
AUC (total area under the plasma concentration vs. time
curve from time zero to infinity), t1/2 (terminal elimina-
tion half-life), CLd (drug clearance due to dialysis), and
Rh (drug removal due to dialysis).
CLd was calculated using the formula: CLd = Qd ×
AUC(dia)/AUC(art), where Qd is the rate of dialysate flow,
AUC(dia) is the area under the dialysate concentration
versus time curve, and AUC(art) is the area under the
arterial plasma concentration versus time curve during
dialysis (see equation 13 of Lee and Marbury [25]). Rh
was calculated using the formula: Rh = CLd × AUC(art)
(see equation 30 of Lee and Marbury [25]).
The log-transformed values of Cmax and AUC and the
untransformed values of t1/2 and Tmax were analyzed using
the analysis of variance (ANOVA), including fixed effects
of sequence (AB or BA), subject within sequence, period
(visit 2 or visit 3), and dosing phase (A or B). The resid-
ual variance of this analysis was used to construct 90%
2-sided CIs on the ratio of the geometric means of phase B
to phase A (after hemodialysis dosing/before hemodialy-
sis dosing) for Cmax and AUC. A 90% 2-sided CI was also
constructed for the difference between dosing phases in
Tmax and t1/2 . These analyses were performed separately
for sildenafil and UK-103,320.
Systolic and diastolic blood pressures and heart rates
were analyzed through 10 hours after the start of
hemodialysis using repeated measures analysis of vari-
ance (ANOVA) of the changes from baseline values,
where baseline was the time point just before the start
of hemodialysis in each dosing phase. Separate analy-
ses of intradialytic and postdialysis blood pressures were
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Table 1. Demographics
Characteristic N = 16
Mean age, years (range) 48 (33−75)
Mean weight, kg (range) 75 (51−107)
Mean duration of end-stage renal 8 (0.4–22)
disease, years (range)
Smoking history, N
Smoker 9
Never smoked 6
Past smoker 1
Race, N
Black 12
White 3
Hispanic 1
Primary cause end-stage renal disease, N
Glomerulonephritis 7
Hypertension 4
Diabetes 3
NSAID-induced 1
Unknown 1
Comorbid diseases, N
Anemia 16
Hypertension, essential unspecified 16
Kidney/ureter disorder 15
Phosphorus metabolism disorder 14
Rheumatism 12
Hyperparathyroidism 11
Pruritic disorder, unspecified 5
Hypercholesterolemia 5
Diabetes mellitus 4
Hypotension, essential unspecified 4
Esophagitis 4
performed. In phase B, the data collected at 4.5 hours and
5.5 hours after the start of hemodialysis (–1 hour and 0
hour, relative to dosing time) were assigned to 4 hours
and 5 hours postbaseline, respectively, to permit compar-
ison by time point with the phase A data. The unadjusted
blood pressures and heart rates were analyzed similarly.
Hypotension was defined as (1)>40 mm Hg decrease in
SBP during hemodialysis, (2) SBP <90 mm Hg, (3) DBP
<40 mm Hg, or (4) any clinical symptoms of decreased
blood pressure.
RESULTS
Subject enrollment and disposition
The 16 subjects ranged in age from 33 to 75 years (mean
47.6 ± 12.1), and had been diagnosed with ESRD for 0.4
to 21.8 years (mean 8.2 ± 6.8; Table 1). Medical histories
(Table 1) and concomitant medication use were consis-
tent with the diagnosis of renal failure and its complica-
tions: 100% were taking anticoagulants and drugs used
to treat anemia, 94% were taking antihypertensive drugs,
94% were taking calcium replacement, 69% were tak-
ing electrolyte replacements, 50% were taking analgesics,
12.5% were taking drugs for hyperlipidemia, and 12.5%
were taking oral antidiabetic drugs. All subjects had ac-
tive histories of anemia and essential hypertension. One
subject discontinued at the end of the first dosing visit
Table 2. Sildenafil and UK-103,320 pharmacokinetic parameters
after a single 50-mg dose of sildenafil administered either before or
after hemodialysis
Ratio of
Phase A Phase B geometric means
(mean ± SD) (mean ± SD) (B/A)a [95% CI]
Sildenafil
AUC ng·h/mL 610 ± 491 564 ± 455
Geometric mean 474 466 98% [84–116]
Cmax ng/mL 139 ± 82 164 ± 121
Geometric mean 117 136 117% [92–148]
Tmax hours 2.10 ± 1.06 1.43 ± 0.94 –1.20 to –0.19b
t1/2 hours 3.07 ± 0.99 3.38 ± 1.18 –0.27 to –0.81
CLd mL/min 8.7 ± 7.4 – –
Rh mg 0.13 ± 0.14 – –
UK-103,320
AUC ng·h/mL 635 ± 420 582 ± 350
Geometric mean 492 47 96% [84−111]
Cmax ng/mL 105 ± 60 124 ± 75
Geometric mean 88 107 122% [105−141]
Tmax hours 2.53 ± 1.87 1.53 ± 0.93 –1.84 to –0.07
t1/2 hours 4.86 ± 2.01 6.31 ± 2.28 0.79 to 2.09c
CLd mL/min 22.2 ± 9.1 – –
Rh mg 0.22 ± 0.16 – –
aPhase A, sildenafil administered 2 hours before hemodialysis; phase B, silde-
nafil administered 2 hours after hemodialysis. For Tmax, and t1/2 , the confidence
intervals shown are for the differences (B–A) of the adjusted arithmetic means
from the analysis of variance.
bP < 0.05.
cP < 0.01.
(phase A) because of noncompliance with study proce-
dures. He was not included in the pharmacokinetic or
hemodynamic analyses.
Pharmacokinetics
The average extent of administered drug bound to
plasma proteins was 95.6% in phase A and 96.3% in phase
B. Drug clearance caused by dialysis was minimal (CLd;
Table 2). Both sildenafil and UK-103,320 were essentially
undialyzed, with less than 1% of the administered dose
recovered in the dialysate (Rh; Table 2).
Mean plasma concentrations of sildenafil were similar
whether sildenafil was administered 2 hours before the
start of hemodialysis (phase A) or 2 hours after the end
of hemodialysis (phase B) (Fig. 2). The rate of absorption
of sildenafil appeared to be somewhat faster when drug
was administered 2 hours after hemodialysis, as indicated
by differences in Tmax and Cmax (Table 2). The extent
of absorption, however, was unaffected by hemodialysis,
as shown by the ratio of geometric means of AUC. The
sildenafil terminal half-life, t1/2 , appeared to be similar
with both dosing schemes.
In general, the trends seen for sildenafil between the 2
dosing schemes were also evident for UK-103,320. How-
ever, the mean t1/2 of the metabolite was shorter when
sildenafil was administered 2 hours before hemodialysis
compared with 2 hours after hemodialysis (Fig. 2). Sta-
tistical analysis showed no significant effects of sequence
(P ≥ 0.25 for all parameters) or period (visit 2 or visit 3;
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Fig. 2. Plasma drug concentrations. Mean
sildenafil (A) and its metabolite, UK-103,320
(B), plasma concentrations were not signif-
icantly different after a single 50-mg dose
of sildenafil administered 2 hours before (◦,
phase A) or 2 hours after (, phase B)
hemodialysis.
P ≥ 0.22 for all parameters) for either sildenafil or UK-
103,320.
Hemodynamics
In phase A, mean blood pressure at dosing was 142/
85 mm Hg, and decreased to 132/77 mm Hg before the
initiation of hemodialysis 2 hours later (Table 3). This
response is consistent with the blood pressure decrease
observed in normal volunteers [26]. During hemodialy-
sis, SBP decreased 5.6 ± 10.4 mm Hg at 30 minutes, and
remained at approximately that level until the conclu-
sion of hemodialysis (Fig. 3, Table 3). DBP during phase
A hemodialysis was variable and followed no discernible
pattern, but decreased on average no more than 7 mm Hg
(Fig. 3).
In phase B, mean blood pressure at the initiation of
hemodialysis was 151/85 mm Hg (Table 3). SBP decreased
5.8 ± 15.5 mm Hg from baseline (initiation of hemodial-
ysis) at 30 minutes, and then for the duration of dialysis
decreased to a level 11 to 15 mm Hg lower than baseline
(Fig. 3, Table 3). Diastolic blood pressure decreased on
average no more than 8 mm Hg, and followed no dis-
cernible pattern (Fig. 3). No statistically significant dif-
ferences in intradialytic SBP, DBP, or heart rate (Fig. 3,
Table 3) were observed between phases A and B. It is
important to note that predialysis weight and intradia-
Table 3. Blood pressure in men administered sildenafil either 2 hours
before or 2 hours after hemodialysis
Blood pressure,
mean ± SD mm Hg
Study event, time after dosing Systolic Diastolic
Phase A: dosing 2 hours before hemodialysis
Sildenafil administration (time 0)a 142 ± 18 85 ± 12
Hemodialysis start (+2.0 h)b 132 ± 20 77 ± 12
Hemodialysis end (+5.5 h) 129 ± 23 71 ± 16
10 hours after hemodialysis start (+12.0 h) 126 ± 15 71 ± 11
Phase B: dosing 2 hours after hemodialysis
Hemodialysis start (−5.5 h)b 151 ± 18 85 ± 12
Hemodialysis end (−2.0 h) 139 ± 22 81 ± 13
Sildenafil administration (time 0)a 131 ± 21 79 ± 14
10 hours after hemodialysis start (+4.5 h) 131 ± 23 79 ± 16
aTime 0 was defined as the time at which sildenafil was administered. In phase
B, administration occurred 5.5 hours after the start of hemodialysis.
bThe time at which hemodialysis started was used as baseline for statistical
analysis of hemodynamic results.
lytic weight change were similar for hemodialysis treat-
ments in the 2 phases. Predialysis weights were 75.4 kg
and 75.5 kg, and mean intradialytic weight changes were
−2.8 kg and –2.7 kg, for phases A and B, respectively.
Intradialytic hypotension was predefined by accepted
criteria (see Methods). Eight subjects who participated in
both phases of the study experienced hypotension by the
predefined criteria: 4 subjects in phase A, and 4 different
subjects in phase B. Of these, only 1 subject in each phase
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Fig. 3. Hemodynamic changes. Systolic
blood pressure (SBP) changes (A) were
significantly different between phase A
(sildenafil administration 2 hours before
hemodialysis (HD); ◦) and phase B (sildenafil
administration 2 hours after HD; ) in the
post-HD period (∗P < 0.05). Diastolic blood
pressure (DBP) changes (B) from the start of
HD were not significantly different between
phase A (◦) and phase B (). There were no
significant changes in heart rate during phase
A (◦) or phase B () (C).
experienced symptoms of hypotension in the absence of
a documented decrease in blood pressure.
After hemodialysis, SBP in phase A initially returned
close to the baseline value, and manifested a mean de-
crease from baseline of 4.2 mm Hg for the 6 hours after
dialysis (Fig. 3). In contrast, SBP in phase B manifested
a decrease of 19.7 mm Hg from the baseline value after
the conclusion of hemodialysis and before sildenafil dos-
ing (Fig. 3), and the mean decrease for the 6 hours after
dialysis was 18.7 mm Hg (P < 0.05 vs. phase A). DBP
behavior following hemodialysis followed no clear pat-
tern in either phase A or B, and no statistically significant
differences were seen (Fig. 3). Heart rate showed a trend
upward in the postdialysis period in both phases (Fig. 3).
Adverse events
Twelve subjects experienced a total of 41 treatment-
emergent adverse events, which were evenly distributed
between the 2 phases of the study, and the events were
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expected in the population of hemodialysis patients. No
subject discontinued because of adverse events. There
was one serious adverse event (hospitalization for right
hip pain caused by degenerative joint disease and right
hip effusion) that occurred more than 2 weeks after dos-
ing and was not related to treatment. No adverse events
were severe. The most commonly reported treatment-
emergent adverse events were asthenia (N = 5), fever
(N = 4), and dizziness (N = 3); of these, only fever was
considered to be related or possibly related to treatment.
All other adverse events occurred 2 or fewer times. Two
episodes of syncope were experienced by 2 different sub-
jects; neither of these was accompanied by a documented
decrease in blood pressure: both were of a “momentary”
or “transient” nature, lasting seconds, and 1 accompanied
signs, symptoms, and laboratory evidence of systemic in-
fection (fever, chills, and positive blood cultures).
DISCUSSION
This study demonstrates that hemodialysis does not
clear sildenafil or its major metabolite UK-103,320, which
are both highly protein-bound. The rate of sildenafil ab-
sorption may be more rapid when hemodialysis precedes
dosing, but the observed differences are not clinically
meaningful. Interestingly, the pharmacokinetic profiles
of sildenafil and UK-103,320 are closer to those observed
in healthy volunteers [17] than those measured in subjects
with severe renal insufficiency [12].
A possible explanation for why sildenafil pharmacoki-
netics can become altered in patients with severe renal
insufficiency may be related to the effects of endogenous
inhibitors of sildenafil metabolism that accumulate in the
absence of normal renal function. A similar circumstance
has been observed for the nonselective b-adrenoceptor
antagonist bopindolol [27]. As is the case for sildenafil,
bopindolol accumulates in patients with chronic renal in-
sufficiency, but its disposition in patients receiving routine
maintenance hemodialysis does not differ significantly
from that in patients with normal renal function [27].
Hence, hemodialysis may remove the endogenous in-
hibitors of metabolism of bopindolol and sildenafil, and
thereby restore the pharmacokinetics closer to that ob-
served in patients with normal renal function.
Intradialytic hypotension was observed with the same
frequency in this study whether the subject took silde-
nafil before hemodialysis or after hemodialysis, and the
rates of hypotension observed were similar to those cited
in the literature of approximately 20% to 30% [28, 29].
SBP decreased on average 5 to 6 mm Hg in the first
30 minutes of hemodialysis therapy, whether or not silde-
nafil was present, but subsequently, intradialytic SBP
showed a trend toward greater lowering in the absence of
sildenafil exposure. No effect or trend could be discerned
for intradialytic DBP or heart rate.
During the 6-hour period after hemodialysis therapy,
SBP was significantly lower when sildenafil was adminis-
tered 2 hours after dialysis had ended, but the majority of
this observed decrease occurred before dosing. DBP be-
havior in the 2 phases of the study was similar but without
a clear pattern, and heart rate tended to increase postdial-
ysis in both phases of the study.
The hemodynamic observations in this study indicate
that sildenafil does not increase the rate of hypotension or
cause concerning blood pressure changes, and these ob-
servations are consistent with those in the literature. In
previous reports, patients on maintenance hemodialysis
have tolerated sildenafil treatment well [8–10], with only
one case report of a hemodialysis patient experiencing
symptoms, including lightheadedness and dizziness after
a 50-mg dose of sildenafil on an interdialytic day, and
blood pressure was 80/50 the following day [30]. Nonethe-
less, the same prudent considerations should be applied
to sildenafil as for the administration of any vasodilator
in the presence of intravascular volume depletion, which
may occur during and after hemodialysis therapy.
These hemodynamic observations may bring the role
of NO in the pathogenesis of intradialytic hypotension
[31] into question. Sildenafil inhibits phosphodiesterase
5, which is responsible for the breakdown of cGMP, the
mediator of the vasodilating effect of NO. If NO were to
be an important component in the genesis of hypotension
during hemodialysis, an increase in cGMP-mediated vas-
cular smooth muscle would be expected to be the patho-
genetic mechanism, and sildenafil would be expected to
potentiate the effect of NO by inhibiting the degradation
of cGMP. Yet neither an increased incidence of hypoten-
sion, nor the behavior of intradialytic blood pressure in
the presence of sildenafil in this study, supports this hy-
pothesis. However, given the limited and selected nature
of the patient population, further confirmation of these
findings will be necessary.
CONCLUSION
The present study demonstrated that sildenafil was not
cleared by hemodialysis, that there were no clinically sig-
nificant differences in the pharmacokinetic profiles of
sildenafil when administered either 2 hours before or af-
ter hemodialysis, and that the pharmacokinetic profiles
resembled more closely those observed in normal volun-
teers than those observed in patients with severe renal
insufficiency. Intradialytic hypotension was not observed
more frequently when sildenafil was administered before
hemodialysis, and the behavior of blood pressure in this
study did not support an important role for NO in the
pathogenesis of intradialytic hypotension.
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